CHEK2 and prostate carcinoma: In the Expert Consensus on HRR Gene Testing and Variant Interpretation in Prostate Cancer, CHEK2 has been explicitly classified as one of the HRR genes associated with the treatment efficacy of PARP inhibitors in prostate cancer (16, 17).